Edition:
United Kingdom

Summit Therapeutics PLC (SMMT.OQ)

SMMT.OQ on NASDAQ Stock Exchange Global Market

1.27USD
8:10pm GMT
Change (% chg)

$-0.16 (-11.19%)
Prev Close
$1.43
Open
$1.40
Day's High
$1.40
Day's Low
$1.25
Volume
20,338
Avg. Vol
16,502
52-wk High
$15.75
52-wk Low
$1.12

Latest Key Developments (Source: Significant Developments)

Summit Therapeutics enters exclusive licence agreement with Eurofarma Laboratórios
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Summit Therapeutics Plc ::SUMMIT THERAPEUTICS PLC HAS ENTERED INTO AN EXCLUSIVE LICENCE AND COMMERCIALISATION AGREEMENT WITH EUROFARMA LABORATÓRIOS SA.AGREEMENT GRANTS EUROFARMA LABORATÓRIOS SA RIGHTS IN LATIN AMERICA TO SUMMIT'S PRECISION ANTIBIOTIC RIDINILAZOLE IN DEVELOPMENT FOR THE TREATMENT OF CDI.SUMMIT RETAINS COMMERCIALISATION RIGHTS IN ALL OTHER COUNTRIES.RIDINILAZOLE IS A TARGETED ANTIBIOTIC THAT HAS THE POTENTIAL AS A FRONTLINE THERAPY TO TREAT INITIAL INFECTION AND PRESERVE PATIENTS' MICROBIOMES TO REDUCE THE RATE OF RECURRENT CDI .  Full Article

UPDATE 1-UK Stocks-Factors to watch on Sept. 20

Sept 20 Britain's FTSE 100 futures were flat ahead of the cash market open on Thursday.

No consensus analysis data available.